Structural Basis for Drug Resistance Mechanisms Against EGFR

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Mutations in the Epidermal Growth Factor Receptor (EGFR) kinase domain lead to resistance against targeted therapies like erlotinib and gefitinib.
• Developing novel compounds effective against all EGFR mutants is crucial for overcoming acquired drug resistance.

Purpose of the Study:

• To predict residues in EGFR that confer drug resistance upon mutation.
• To identify a novel lead compound with broad efficacy against wild-type (WT) and mutant EGFR.

Main Methods:

• Assessed EGFR residue positions interacting with erlotinib and gefitinib using conservation index, binding site RMSD, protein stability, and binding affinity changes.
• Employed a structural screening protocol and molecular docking to identify and evaluate novel compounds.
• Utilized computational models of wild-type and mutant EGFR.

Main Results:

• Identified Lys 745, Cys 797, Asp 800, and Thr 854 as key positions likely to confer resistance by altering drug binding without destabilizing protein or ATP binding.
• A novel compound, DHO, demonstrated superior binding affinity across all evaluated EGFR models compared to erlotinib and gefitinib.
• DHO showed potential for inhibiting wild-type, mutant, and single nucleotide polymorphism (SNP) variants of EGFR.

Conclusions:

• The identified EGFR positions provide insights into mechanisms of drug resistance.
• Compound DHO represents a promising lead for developing next-generation EGFR inhibitors.
• This study paves the way for designing drugs effective against a wide spectrum of EGFR variants, including resistant mutations.